Oxurion Announces Extraordinary and Annual Shareholders’ Meetings

Leuven, Belgium, Boston, MA, US - April 1, 2022 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announces extraordinary and annual shareholders’ meetings to be held on Tuesday 3 May 2022 at 10:00 AM (CET) and 2:00 PM (CET), respectively.

The convening notice and other documents pertaining to the shareholders’ meetings can be consulted on our website Oxurion/shareholders.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to better preserve vision in patients with retinal vascular disorders including diabetic macular edema (DME), the leading cause of vision loss in diabetic patients worldwide as well as other conditions, including wet age-related macular degeneration (wet AMD) and macular edema following retinal vein occlusion (ME-RVO). Oxurion is aiming to build a leading global franchise in the treatment of retinal vascular disorders based on the successful development of its two novel therapeutics. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. THR-687 is a highly selective pan-RGD integrin antagonist that is being developed as a potential first line therapy for DME patients as well as wet AMD and potentially ME-RVO. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.